The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
The FDA approved Xultophy 100/3.6 for the reduction of A1c in adults with type 2 diabetes inadequately controlled by basal insulin or liraglutide alone.
The FDA approved Xultophy 100/3.6 for the reduction of A1c in adults with type 2 diabetes inadequately controlled by basal insulin or liraglutide alone.
The FDA approved Xultophy 100/3.6 for the reduction of A1c in adults with type 2 diabetes inadequately controlled by basal insulin or liraglutide alone.
The FDA has approved Soliqua 100/33 for the treatment of adults with type 2 diabetes that has been inadequately controlled with basal insulin or lixisenatide.
The FDA has approved Soliqua 100/33 for the treatment of adults with type 2 diabetes that has been inadequately controlled with basal insulin or lixisenatide.
